Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
AACR 2024 preview – clinical highlights and lowlights
The 2024 AACR abstract title drop features several noteworthy clinical studies.
Sana regains some of its shine
The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.
Two allogeneic cell therapy switches in a day
Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.
Crispr abandons first-generation Car-T projects
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
